{"nctId":"NCT02793622","briefTitle":"Prevention of Malaria in HIV-uninfected Pregnant Women and Infants","startDateStruct":{"date":"2016-09"},"conditions":["Malaria"],"count":782,"armGroups":[{"label":"Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy"]},{"label":"Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy"]}],"interventions":[{"name":"Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy","otherNames":["Kamsidar (KPI)"]},{"name":"Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy","otherNames":["Duo-Cotexin (Holley-Cotec)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound\n* Estimated gestational age between 12-20 weeks\n* Confirmed to be HIV uninfected by rapid test\n* 16 years of age or older\n* Resident of Busia District, Uganda\n* Provision of informed consent by the pregnant woman for herself and her unborn child\n* Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol\n* Plan to deliver in the hospital\n\nExclusion Criteria:\n\n* History of serious adverse event to SP or DP\n* Active medical problem requiring inpatient evaluation at the time of screening\n* Intention of moving outside of Busia District, Uganda\n* Chronic medical condition requiring frequent medical attention\n* Prior SP preventive therapy or any other antimalarial therapy during this pregnancy\n* Early or active labor (documented by cervical change with uterine contractions)","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Deliver With a Composite Adverse Birth Outcome","description":"Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (\\< 2500 gm); 2) Preterm delivery (\\< 37 weeks gestational age); 3) Small for gestational age (\\< 10th percentile relative to an external growth reference)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Malaria in Infants","description":"episodes per person year","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":null},{"groupId":"OG001","value":"1.71","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Gestational Age in Weeks at Birth","description":"Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":"1.9"},{"groupId":"OG001","value":"39.6","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Prevalence of Placental Malaria by Histology","description":"Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Placental Parasitemia","description":"Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Maternal Malaria","description":"Maternal blood positive for malaria parasites by microscopy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"All grade 3 and 4 adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Anemia in Pregnant Women","description":"hemoglobin \\< 11 g/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Anemia in Infants","description":"Defined as the proportion with hemoglobin \\< 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).\n\nThis is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Asymptomatic Parasitemia in Pregnant Women","description":"Proportion of routine monthly samples positive for parasites by microscopy and LAMP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"519","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Asymptomatic Parasitemia in Infants","description":"Proportion of routine monthly samples positive for parasites by microscopy and LAMP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"357","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Complicated Malaria in Infants","description":"Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hospital Admissions in Infants","description":"Admission to the pediatric ward for any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Infant Mortality Rate","description":"Any deaths occurring after birth","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":375},"commonTop":["Abdominal pain","Cough","Headache","Pyuria","Diarrhea"]}}}